- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.Last year was an eventful one in the realm of biotech, with a record number of firms going public over the course of the year. Aytu BioScience Inc. (NASDAQ: AYTU), led by its founders and biopharmaceutical entrepreneurs Jarrett and...
First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 PatientsENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 / Aytu BioScience, Inc.
Aerojet Rocketdyne Holdings, Inc. (NYSE: AJRD)
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Neos Therapeutics, Inc. (NasdaqGS: NEOS) to Aytu BioScience, Inc. (NasdaqGS: AYTU). Under the terms of the proposed transaction, shareholders of Neos will receive only 0.1088 shares of Aytu for each share of Neos that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the co...
ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc.
ENGLEWOOD, CO / ACCESSWIRE / December 14, 2020 / Aytu BioScience, Inc.
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Neos Therapeutics, Inc. (NASDAQ: NEOS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Aytu BioScience, Inc. (NASDAQ: AYTU). Click here to learn more and participate in the action.On December 10, 2020, Neos announced that it had signed a...
WILMINGTON, Del., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Neos Therapeutics, Inc. (“Neos”) (NASDAQ GS: NEOS) regarding possible breaches of fiduciary duties and other violations of law related to Neos’ agreement to be acquired by Aytu BioScience, Inc. (“Aytu”) (NASDAQ GS: AYTU). Under the terms of the agreement, Neos’ shareholders will receive 0.1088 shares of Aytu common stock per share. To learn more about this investigation and your rights,...